Last reviewed · How we verify
Crisaborole ointment, 2%
Crisaborole inhibits phosphodiesterase 4 (PDE4), reducing inflammatory mediator production in immune cells.
Crisaborole inhibits phosphodiesterase 4 (PDE4), reducing inflammatory mediator production in immune cells. Used for Mild to moderate atopic dermatitis.
At a glance
| Generic name | Crisaborole ointment, 2% |
|---|---|
| Also known as | Eucrisa |
| Sponsor | Pfizer |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
PDE4 inhibition increases intracellular cAMP levels in immune and inflammatory cells, suppressing the production of pro-inflammatory cytokines and chemokines. This reduces the inflammatory cascade characteristic of atopic dermatitis, leading to decreased skin inflammation, itching, and lesion severity when applied topically.
Approved indications
- Mild to moderate atopic dermatitis
Common side effects
- Application site burning or pain
- Application site irritation
- Pruritus at application site
Key clinical trials
- Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (PHASE4)
- Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis (PHASE4)
- Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis (PHASE3)
- Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. (NA)
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- Eucrisa for Atopic Dermatitis (PHASE1)
- Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis (PHASE4)
- Topical Crisaborole in Patients with Alopecia Areata (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Crisaborole ointment, 2% CI brief — competitive landscape report
- Crisaborole ointment, 2% updates RSS · CI watch RSS
- Pfizer portfolio CI